Humasis Co

Humasis Co Intangible Assets

The Intangible Assets of Humasis Co (205470.KQ) as of Nov 11, 2026 is 1.41 B KRW.

Intangible Assets

1.41 BKRW

Last updated:

Intangible Assets of Humasis Co is 2024 1.41 B KRW. Intangible Assets of Humasis Co was 2023 0.00 KRW. It decreases by % higher compared to the previous year.

The Humasis Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
22.00 M KRW
Jan 1, 2018
44.00 M KRW
Jan 1, 2019
57.00 M KRW
Jan 1, 2020
43.00 M KRW
Jan 1, 2021
76.62 M KRW
Jan 1, 2022
119.28 M KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
1.41 B KRW
The Humasis Co Intangible Assets history
YEARIntangible AssetsYoY
1.41 BKRW—
0.00KRW-100.00%
119.28 MKRW+55.69%
76.62 MKRW+78.17%
43.00 MKRW-24.56%
57.00 MKRW+29.55%
44.00 MKRW+100.00%
22.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Intangible Assets of Humasis Co is 1.41 B KRW in 2024.

On Eulerpool you can find the complete historical development of Intangible Assets Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humasis Co

All Key Metrics — Humasis Co